We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -4.55% | 10.50 | 10.00 | 11.00 | 11.00 | 10.50 | 11.00 | 1,004,092 | 14:47:52 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 2.19M | -20.13M | -0.0624 | -1.68 | 35.49M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/11/2024 14:10 | Well there should be a modicum of humility from some of the bulls here. The bearish view concerning a fundraise was actually correct and similarly with missing the revenue target. | boris cobaka | |
15/11/2024 13:51 | Remember that loon adw? Yasx? REMEMBER THE FUD AT 7.50 BID? | atmysignal | |
15/11/2024 13:49 | The assay identified CTCs in 91% (29/32) of metastatic lung cancer patients assessed as part of an ongoing longitudinal study, presenting with a range of phenotypes. PD-L1 positive CTCs were observed in 72% of patients with a PD-L1 positive tissue biopsy and in 27% of patients with a PD-L1 negative tissue biopsy, demonstrating the potential for improved assessment of tumour heterogeneity through analysis of PD-L1 status in CTCs. | outsizeclothes.com | |
15/11/2024 12:32 | I am only an amateur chartist but to me it looks as though the price has finally broken above its downtrend. Any more knowledgeable chartists out there care to comment. | mesquida | |
15/11/2024 12:32 | 698 bringing out the aliases again. Sad | muffster | |
15/11/2024 11:20 | course they are. Keep telling yerself and eventually it'll be so... meanwhile back in the lab.... | boris cobaka | |
15/11/2024 10:53 | boris - I disagree they are not PI profit takers. The sells are coming from one source and they are selling into PI buyers on the non-RNS updates. There are thousands of methods out there to improve cancer drugs and treatments but it does not mean big pharma will adopt them all on an industrial scale. Sadly Parsortix seems to fall into this category. | pwhite73 | |
15/11/2024 10:40 | full marks for effort pwhite | boris cobaka | |
15/11/2024 10:39 | I suspect some traders taking profits from acquiring sub 9p. Wonder if they'll be able to buy back cheaper.... | boris cobaka | |
15/11/2024 10:23 | For crying out loud look at the reds from 10:11 - 10:14. D'you think its individual retail shareholders all deciding to sell at the same time. The sells are coming from one source and the reason why it still can't climb above the placing price of 15p because the next placing is 10p in my opinion of course. | pwhite73 | |
15/11/2024 10:22 | POLX Polarean Imaging about to break out above 2p soon. Mcap even less than AGL but cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 155p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. | m_night10 | |
15/11/2024 09:53 | From Half Year Report in September "Prioritising investment towards growth of the large pharma strategy and reducing investment in the products side is intended to maximise ANGLE's commercial opportunity and is now anticipated to deliver cashflow positive trading in the second half of 2026; and the Company is funded to execute on this plan" | seball | |
15/11/2024 09:52 | You're wasting your time here. | puphead | |
15/11/2024 09:51 | Remember the ones scaring you to sell at 7.50 bid | atmysignal | |
15/11/2024 09:51 | Pwhite yet again a contrarian investor / signal to buy Only PATT comes close to this 100 percent track record Quite unbelievable really | washingmachine | |
15/11/2024 09:48 | "When AIM/small cap companies tell you they are funded until 202X it does not mean they won't be placing until after that date it means they have discussed funding with their brokers and nomads who have assured they they will be able to raise money on the capital markets up to and beyond that date"Please send me whatever youre smoking | zeus19 | |
15/11/2024 09:43 | zeus19 - "deliver cashflow positive trading in the second half of 2026; and the Company is funded to execute on this plan" When AIM/small cap companies tell you they are funded until 202X it does not mean they won't be placing until after that date it means they have discussed funding with their brokers and nomads who have assured them they will be able to raise money on the capital markets up to and beyond that date. | pwhite73 | |
15/11/2024 09:39 | Keeps going NT on my platform. | bsg | |
15/11/2024 09:25 | 6 weeks ago, the company stated:"Prioritising investment towards growth of the large pharma strategy and reducing investment in the products side is intended to maximise ANGLE's commercial opportunity and is now anticipated to deliver cashflow positive trading in the second half of 2026; and the Company is funded to execute on this plan"Key part being "the Company is funded to execute on this plan" And youre talking about a placing... | zeus19 | |
15/11/2024 09:09 | The date is 11th September 2024 it is not new. | pwhite73 | |
15/11/2024 08:44 | seball, is this a new note, when exactly was It published ? | mesquida | |
15/11/2024 08:44 | volume spike t'other day was not for nowt... First nibble. Tight lines.... | boris cobaka |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions